Brain metastases as late breast cancer relapse. Single institution experience and review of the literature

Journal of B.U.ON.

Volumn 14, Issue 2, 2009, Pages 225-228

  Tomasevic, Zorica ^a   Radosevic Jelic, Lj ^a   Jovanovic, D ^a   Milovanovic, Z ^a   Tomasevic, Z M ^a   Jelic, S ^a   Borojevic, N ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

Brain metastases; Breast cancer; HER2 3+; Late relapse

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER GROWTH; CANCER INCIDENCE; CANCER RELAPSE; HEALTH CENTER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MEDICAL LITERATURE;

ADULT; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INCIDENCE; MEDICAL RECORDS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 67651031005     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Chang E, Lo S. Management of central nervous system metastases from breast cancer. Oncologist 2003; 8: 398-410.
2. Lassman A, DeAngelis L. Brain metastases. Neurol Clin 2003; 21: 1-23.
3. Lin N, Bellon J, Winer E. CNS metastases in breast cancer. J Clin Oncol 2004; 3608-3617.
4. Tsukada Y, Fouad A, Pickren JW, Lane WW. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 1983; 52: 2349-2354.
5. Clayton AJ, Danson S, Jolly S et al. Incidence of central nervous system metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004; 91: 639-643.
6. Bendell JC, Domchec SM, Burstein HU et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97: 2972-2977.
7. Weitzen R, Zach L, Kaufman B et al. High incidence of brain metastasis in patients on trastuzumab for advanced breast cancer. Proc Am Soc Clin Oncol 2002; 20: 31b (abstr 1936).
8. Di Stefano A, Yong Yap, Hortobagy GN, Blumenschein GR. The natural history of breast cancer patients with brain metastases. Cancer 1979; 44: 1913-1918.
9. Piccirilli M, Sassun TE, Brogna C, Giangaspero F, Salvati M. Late brain metastases from breast cancer: Clinical remarks on 11 patients and review of the literature. Tumori 2007; 93: 150-154.
10. Slimane K, Andre F, Delalonge S et al. Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol 2004; 15: 1640-1644.
11. Gabos Z, Sinba R, Hanson J, Chauhan N, Hugh J, Mackey JR. Prognostic significance of human epidermal growth factor receptor for the development of brain metastasis in newly diagnosed breast cancer. J Clin Oncol 2006; 24: 5658-5663.
12. Muller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-56.
13. Salvucci O, Bouchard A, Baccarella A et al. The role of CXCR4 receptor expression in breast cancer A large tissue microarray study. Breast Cancer Res Treat 2006; 97: 275-283.
14. Lee BC, Lee TH, Avraham S, Avraham HK. Involvement of the chemokine receptor CXCR4 and its ligand stromal cell derived factor 1 alpha in breast cancer cell migration through human brain micro vascular endothelial cells. Mol Cancer Res 2004; 2: 327-338.
15. Linderhaldm B, Grankvist K, Wilking N. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol 2000; 18: 1423-1431.
16. Schem C, Stark A, Mehdom H, Jonat W, Maass N. Expression of metastasis suppressor gene maspin in breast cancer brain metastases. J Clin Oncol 2006; 24(Suppl) 18S: 20057 (abstr).
17. Stewart JF, King RJ, Sexston SA, Millis RR, Rubens RD, Hayward JL. Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. Eur J Cancer 1981; 17: 449-453.
18. Sparrow GE, Rubens RD. Brain metastases from breast cancer: clinical course, prognosis and influence of treatment. Clin Oncol 1981; 7: 291-301.